Insider Transactions in Q1 2023 at Precision Biosciences Inc (DTIL)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2023
|
Michael Amoroso President and CEO |
SELL
Open market or private sale
|
Direct |
46,999
-40.61%
|
$0
$0.82 P/Share
|
|
Mar 21
2023
|
Michael Amoroso President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
102,535
+46.98%
|
-
|
|
Mar 17
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+7.53%
|
$0
$0.86 P/Share
|
|
Mar 06
2023
|
Alan List Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,473
-19.85%
|
$9,473
$1.07 P/Share
|
|
Mar 06
2023
|
Dario Scimeca General Counsel and Secretary |
SELL
Open market or private sale
|
Direct |
12,172
-19.56%
|
$12,172
$1.07 P/Share
|
|
Mar 03
2023
|
Alan List Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,453
+38.17%
|
-
|
|
Mar 03
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
27,558
+30.69%
|
-
|
|
Mar 03
2023
|
J. Jefferson Smith Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,576
+0.8%
|
-
|
|
Mar 03
2023
|
Shane Barton VP & Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
12,722
+37.26%
|
-
|
|
Mar 03
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,071
+18.46%
|
-
|
|
Feb 28
2023
|
Dario Scimeca General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,163
+5.87%
|
$0
$0.95 P/Share
|
|
Feb 28
2023
|
J. Jefferson Smith Chief Research Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,157
+0.63%
|
$0
$0.95 P/Share
|
|
Feb 28
2023
|
John Alexander Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,605
+6.23%
|
$0
$0.95 P/Share
|